| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF03349263 |
| P698 | PubMed publication ID | 18997495 |
| P50 | author | Annamaria Colao | Q64495559 |
| Ezio Ghigo | Q88945694 | ||
| Andrea Giustina | Q90704065 | ||
| P2093 | author name string | A Grossman | |
| S Melmed | |||
| A Hoffman | |||
| A Barkan | |||
| European Neuroendocrine Association | |||
| F Casanueva | |||
| M Sheppard | |||
| P Chanson | |||
| Pituitary Society | |||
| S Lamberts | |||
| P2860 | cites work | Differential effect sizes of growth hormone replacement on Quality of Life, well-being and health status in growth hormone deficient patients: a meta-analysis | Q24813917 |
| Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt | Q28188199 | ||
| Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis | Q28258638 | ||
| Drugs and valvular heart disease | Q28281805 | ||
| Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study | Q28283021 | ||
| Pituitary surgery for the management of acromegaly | Q30306030 | ||
| Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria | Q30307884 | ||
| Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas | Q32086716 | ||
| Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3. | Q32131124 | ||
| Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men. | Q33223290 | ||
| Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. | Q44645577 | ||
| Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy | Q44791811 | ||
| Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system. | Q44948397 | ||
| Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing | Q44968730 | ||
| Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate | Q44974521 | ||
| Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group | Q33422510 | ||
| Life expectancy following surgery for pituitary tumours | Q33704131 | ||
| Criteria for cure of acromegaly: a consensus statement | Q33848161 | ||
| Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity | Q33897208 | ||
| Epidemiology of acromegaly | Q33925493 | ||
| Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group | Q33939854 | ||
| Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment | Q34086691 | ||
| Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain | Q34118556 | ||
| Fracture rates in patients with growth hormone deficiency | Q34123391 | ||
| Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study | Q34141753 | ||
| Guidelines for acromegaly management | Q34147940 | ||
| Acromegaly and cancer: not a problem? | Q34302031 | ||
| Clinical perspective: acromegaly and cancer: a problem | Q34302038 | ||
| Insulin-like growth factors and neoplasia. | Q34330521 | ||
| Long-acting somatostatin analog therapy of acromegaly: a meta-analysis | Q34417750 | ||
| Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline | Q34517215 | ||
| Somatostatin analogs in acromegaly | Q34727752 | ||
| Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly | Q35041716 | ||
| Clinical effectiveness and cost-effectiveness of growth hormone in adults in relation to impact on quality of life: a systematic review and economic evaluation | Q35065165 | ||
| Primary medical therapy for acromegaly | Q35086868 | ||
| Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm | Q35558892 | ||
| Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis | Q35608889 | ||
| Systemic complications of acromegaly: epidemiology, pathogenesis, and management | Q35652696 | ||
| Pitfalls in the biochemical assessment of acromegaly | Q35670498 | ||
| Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis | Q35729469 | ||
| Evolving concepts in the quest for advanced therapeutic analogues of somatostatin. | Q35743374 | ||
| Growth hormone outgrows growth | Q35814492 | ||
| Clinical manifestations of acromegaly. | Q35816127 | ||
| Growth hormone therapy and quality of life in adults and children | Q35817025 | ||
| Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly | Q35990990 | ||
| Current guidelines for adult GH replacement | Q36042463 | ||
| Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. | Q36068551 | ||
| Current diagnostic guidelines for biochemical diagnosis of acromegaly. | Q36070022 | ||
| Experience in management of 51 non-functioning pituitary adenomas: indications for post-operative radiotherapy | Q36091578 | ||
| Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly | Q45055382 | ||
| Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. | Q45055386 | ||
| AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly | Q45070244 | ||
| Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients | Q45142795 | ||
| Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria | Q45178342 | ||
| Clinically silent somatotropinomas may be biochemically active | Q45238675 | ||
| Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly | Q46483203 | ||
| Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. | Q46580971 | ||
| Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist | Q46620956 | ||
| Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl | Q46630241 | ||
| Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant | Q46632235 | ||
| Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. | Q47232476 | ||
| Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders | Q47324978 | ||
| Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements | Q47386656 | ||
| Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly | Q47799277 | ||
| Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience | Q48123449 | ||
| Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly | Q48474600 | ||
| Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life | Q48560709 | ||
| Diagnosis and treatment of acromegaly complications | Q48597328 | ||
| Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. | Q48921808 | ||
| Mortality in acromegaly | Q48948083 | ||
| Epidemiology of acromegaly in the Newcastle region. | Q50592918 | ||
| Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. | Q50862943 | ||
| Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study. | Q50921492 | ||
| Anaesthetic complications of acromegaly. | Q51408935 | ||
| Laryngoscopy and fibreoptic intubation in acromegalic patients. | Q51516489 | ||
| Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. | Q51548906 | ||
| Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. | Q51552603 | ||
| Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms. | Q52041109 | ||
| Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. | Q52533086 | ||
| Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. | Q52866841 | ||
| The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. . | Q53328360 | ||
| Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency. | Q53463676 | ||
| Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant. | Q53663628 | ||
| A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. | Q53925757 | ||
| Octreotide as primary therapy for acromegaly. | Q53945888 | ||
| Which adults develop side-effects of growth hormone replacement? | Q54005038 | ||
| Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. | Q54040277 | ||
| Presurgical Octreotide: treatment in acromegaly | Q57189460 | ||
| New approach to the diagnosis of growth hormone deficiency in adults | Q71046146 | ||
| Acromegaly--the place of the neurosurgeon | Q71434255 | ||
| Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients | Q71434259 | ||
| Growth hormone treatment in hypopituitary GH deficient adults reduces circulating cortisol levels during hydrocortisone replacement therapy | Q71509888 | ||
| Effect of the acid-labile subunit on the binding of insulin-like growth factor (IGF)-binding protein-3 to [125I]IGF-I | Q71687667 | ||
| Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly | Q71825695 | ||
| Determinants of clinical outcome and survival in acromegaly | Q72106091 | ||
| Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations | Q72722608 | ||
| Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls | Q73086769 | ||
| Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly | Q73270923 | ||
| Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly | Q73353972 | ||
| Comment on growth hormone therapy and retinal changes mimicking diabetic retinopathy | Q73484081 | ||
| Effect of octreotide pretreatment on surgical outcome in acromegaly | Q73784958 | ||
| American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children--2003 update | Q73806005 | ||
| The pathology of median neuropathy in acromegaly | Q74039540 | ||
| Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults | Q74154673 | ||
| Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency | Q74189077 | ||
| Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years | Q74379964 | ||
| Factors influencing mortality in acromegaly | Q75425059 | ||
| Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly | Q77549282 | ||
| Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study | Q77825110 | ||
| Preoperative short-term administration of octreotide for facilitating transsphenoidal removal of invasive growth hormone-secreting macroadenomas | Q78098583 | ||
| A comparison of lanreotide and octreotide LAR for treatment of acromegaly | Q78196995 | ||
| Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients | Q79483043 | ||
| Low bone mass is an infrequent feature of the adult growth hormone deficiency syndrome in middle-age adults and the elderly | Q79735473 | ||
| Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening | Q80542264 | ||
| Long-term outcome of patients with acromegaly and congestive heart failure | Q80974718 | ||
| Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years | Q81053012 | ||
| Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women | Q81210432 | ||
| Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease? | Q81493514 | ||
| Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly | Q82224016 | ||
| Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy | Q83104858 | ||
| BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide | Q83178774 | ||
| Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient | Q95751073 | ||
| ??? | Q64786060 | ||
| A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly | Q36096732 | ||
| Treatment of the adult growth hormone deficiency syndrome: directions for future research | Q36205256 | ||
| Consensus statement: medical management of acromegaly | Q36328614 | ||
| GH deficiency in the adult and bone. | Q36329239 | ||
| Normal growth and development in the absence of hepatic insulin-like growth factor I | Q36394699 | ||
| Resistance to somatostatin analogs in acromegaly: an evolving concept? | Q36428225 | ||
| Novel chimeric somatostatin analogs: facts and perspectives. | Q36782654 | ||
| Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors | Q37374477 | ||
| The oncogenic potential of autocrine human growth hormone in breast cancer | Q37589546 | ||
| Increased cerebrovascular mortality in patients with hypopituitarism | Q38505728 | ||
| Premature mortality due to cardiovascular disease in hypopituitarism | Q38516015 | ||
| Sandostatin LAR in acromegalic patients: long-term treatment | Q39459898 | ||
| Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients | Q39711398 | ||
| An audit of outcome of treatment in acromegaly. | Q40823730 | ||
| Current treatment guidelines for acromegaly | Q40846028 | ||
| Human growth hormone and human aging | Q40906146 | ||
| Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience | Q41328719 | ||
| Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? | Q42166137 | ||
| Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study | Q42444212 | ||
| Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly | Q42460622 | ||
| Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results | Q42462304 | ||
| Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly | Q42464202 | ||
| The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. | Q42475367 | ||
| Outcome of surgery for acromegaly--the experience of a dedicated pituitary surgeon | Q42480616 | ||
| Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution | Q42482027 | ||
| Transsphenoidal surgery in acromegaly investigated by intraoperative high-field magnetic resonance imaging. | Q42482045 | ||
| Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance | Q42491293 | ||
| Insulin-like growth factor I and daily growth hormone profile in the assessment of active acromegaly | Q42498390 | ||
| Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery | Q42501709 | ||
| The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly | Q42513535 | ||
| The effect of hypopituitarism on life expectancy | Q42522104 | ||
| Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. | Q42632056 | ||
| Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly | Q42672411 | ||
| Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size | Q42684884 | ||
| A nationwide survey of mortality in acromegaly | Q43517206 | ||
| Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly | Q43633900 | ||
| Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro | Q43635418 | ||
| Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre | Q43675070 | ||
| Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist | Q43816270 | ||
| Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly | Q43852939 | ||
| Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly | Q43889397 | ||
| A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal | Q43946926 | ||
| Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T(4) therapy become mandatory? | Q43982415 | ||
| Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up | Q44088997 | ||
| Growth hormone receptor antagonist improves insulin resistance in acromegaly | Q44210599 | ||
| Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission | Q44547492 | ||
| Lanreotide 60 mg, a New Long-Acting Formulation: Effectiveness in the Chronic Treatment of Acromegaly | Q44645535 | ||
| P433 | issue | 9 | |
| P921 | main subject | growth hormone deficiency | Q369262 |
| P304 | page(s) | 820-838 | |
| P577 | publication date | 2008-09-01 | |
| P1433 | published in | Journal of Endocrinological Investigation | Q15766847 |
| P1476 | title | Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults | |
| P478 | volume | 31 |
| Q37061155 | A consensus on the diagnosis and treatment of acromegaly complications |
| Q95827414 | A practical approach to acromegaly management in Latin America |
| Q37890467 | Acromegaly: presentation, morbidity and treatment outcomes at a single centre. |
| Q38456569 | Clinical assays for quantitation of insulin-like-growth-factor-1 (IGF1). |
| Q48669032 | Comparison of primary octreotide-lar and surgical treatment in newly diagnosed patients with acromegaly |
| Q38847622 | Current and future medical treatments for patients with acromegaly. |
| Q39818772 | Current management practices for acromegaly: an international survey. |
| Q36140969 | Diagnosing growth hormone deficiency in adults. |
| Q50063161 | Diagnostics and treatment of acromegaly : Necessity for targeted monitoring of comorbidities |
| Q30604166 | Double, synchronous pituitary adenomas causing acromegaly and Cushing's disease. A case report and review of literature |
| Q33794409 | Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly |
| Q39673688 | Effectofrosiglitazoneonserum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: Results froma pilot phase 2 study |
| Q38210369 | Effects of low dose versus high dose human growth hormone on body composition and lipids in adults with GH deficiency: a meta-analysis of placebo-controlled randomized trials |
| Q49349775 | Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly |
| Q37531060 | Frequency of multiple endocrine neoplasia type 1 in a group of patients with pituitary adenoma: genetic study and familial screening |
| Q38079133 | Glucocorticoids and the regulation of growth hormone secretion |
| Q34200821 | Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance |
| Q51749078 | High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures. |
| Q53720920 | How to improve effectiveness of pegvisomant treatment in acromegalic patients. |
| Q40470381 | Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. |
| Q60929840 | Incidence rate and risk factors of early repolarization in patients with growth hormone-secreting pituitary adenoma: a cohort study |
| Q39790642 | Intraoperative Magnetic Resonance Imaging During Endoscopic Transsphenoidal Surgery of Growth Hormone-Secreting Pituitary Adenomas. |
| Q38111437 | Investigational therapies for acromegaly |
| Q48201657 | Laboratory investigation of acromegaly: is basal or random GH > 0.4 µg/L in the presence of normal serum IGF-1 an important result? |
| Q28075372 | Mass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular disease |
| Q38209810 | Muscle-bone and fat-bone interactions in regulating bone mass: do PTH and PTHrP play any role? |
| Q85870465 | Optimal use of pegvisomant in acromegaly: are we getting there? |
| Q33725999 | Pegvisomant in acromegaly: an update |
| Q84218635 | Pituitary autoimmunity is associated with hypopituitarism in patients with primary empty sella |
| Q53487796 | Prevalence of AIP mutations in a series of Turkish acromegalic patients: are synonymous AIP mutations relevant? |
| Q37704168 | Primary empty sella: Why and when to investigate hypothalamic-pituitary function |
| Q43490043 | Reappraisal of serum insulin-like growth factor-I (IGF-1) measurement in the detection of isolated and combined growth hormone deficiency (GHD) during the transition period |
| Q48427051 | Screening for acromegaly in adult patients not reporting enlargement of the extremities, but with arterial hypertension associated with another comorbidity of the disease |
| Q37612231 | The current status of IGF-I assays--a 2009 update |
| Q34002769 | The rational use of pituitary stimulation tests |
| Q24626819 | Treatment of Cushing disease: overview and recent findings |
| Q87336122 | Vitamin D-binding protein: one more piece in the puzzle of acromegalic osteopathy? |
Search more.